(redirected from Menopur)


a purified preparation of gonadotropins extracted from the urine of postmenopausal women, containing follicle-stimulating hormone and luteinizing hormone; used to treat male hypogonadism, to induce ovulation and pregnancy in certain infertile, anovulatory women, and to increase the numbers of oocytes for patients attempting conception using assisted reproductive technologies such as gamete intrafallopian transfer (GIFT) or in vitro fertilization; administered intramuscularly.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


Menopur, Repronex

Pharmacologic class: Hormone

Therapeutic class: Exogenous gonadotropin

Pregnancy risk category X


Simulates action of follicle-stimulating hormone (FSH) by promoting follicular growth and maturation


Injection (powder or pellet for reconstitution): 75 international units luteinizing hormone (LH); 150 international units LH and 150 international units FSH activity/vial

Indications and dosages

Controlled ovarian stimulation in patients with oligoanovulation

Women: Dosage individualized. Recommended dosage is 150 international units I.M. or subcutaneously daily during first 5 days of treatment, with subsequent dosages adjusted based on response. Adjust dosage no more often than every 2 days, and don't exceed 75 to 150 international units per adjustment. Maximum daily dosage is 450 international units. Dosing beyond 12 days is not recommended. If response is appropriate, human chorionic gonadotropin (hCG) should be given I.M. 1 day after last menotropins dose.

Assisted reproductive technologies

Women: In patients who've received gonadotropin-releasing hormone agonists or antagonist pituitary suppression, recommended initial dosage is 225 international units I.M. or subcutaneously, with subsequent dosage adjustments based on response. Adjust dosage no more often than every 2 days, and don't exceed 75 to 150 international units per adjustment. Maximum daily dosage is 450 international units. Dosing beyond 12 days isn't recommended. Once adequate follicular development appears, hCG is given to induce follicular maturation in preparation for oocyte retrieval.


• Hypersensitivity to drug

• High FSH levels (indicating primary ovarian failure)

• Abnormal bleeding of undetermined origin

• Uncontrolled thyroid or adrenal dysfunction

• Organic intracranial lesion (such as pituitary tumor)

• Causes of infertility other than anovulation (unless patient is candidate for in vitro fertilization)

• Ovarian cysts or enlargement not caused by polycystic ovarian syndrome

• Pregnancy


Use cautiously in:

• renal or hepatic insufficiency (safety and efficacy not established)

• breastfeeding patients.


• Know that drug may be given either I.M. or subcutaneously.

• To reconstitute powder or pellet for injection, add accompanying 2 ml of 0.9% sodium chloride injection to vial.

• Inject immediately after reconstitution. Discard unused portion.

• Rotate injection sites.

• Use lower abdomen for subcutaneous injection.

• Withhold hCG if serum estradiol level exceeds 2,000 pg/ml or abdominal pain occurs.

Adverse reactions

CNS: headache, malaise, dizziness, cerebrovascular accident

CV: tachycardia, venous thrombophlebitis, arterial occlusion, arterial thromboembolism

GI: nausea, vomiting, diarrhea, abdominal cramps and distention, hemoperitoneum

GU: ovarian enlargement with pain, gynecomastia, ovarian cysts, multiple births, ovarian hyperstimulation syndrome (OHSS), ectopic pregnancy

Metabolic: electrolyte imbalances

Musculoskeletal: muscle aches, joint pain

Respiratory: dyspnea, tachypnea, atelectasis, adult respiratory distress syndrome, pulmonary embolism, pulmonary infarction

Skin: rash

Other: fever, hypersensitivity reaction, anaphylaxis


None significant

Patient monitoring

• Know that before starting menotropins/hCG therapy to induce ovulation and pregnancy, patient should undergo gynecologic and endocrine evaluation with hysterosalpingogram to rule out pregnancy and neoplastic lesions.

• Assess patient to confirm anovulation. Obtain urinary gonadotropin levels as ordered to rule out primary ovarian failure. (Male partner's fertility should be evaluated, also).

• In older females (who have greater risk of anovulatory disorders and endometrial cancer), assess cervical dilation and curettage results.

• Evaluate patient for expected ovarian stimulation without hyperstimulation.

Monitor for early indications of OHSS-severe pelvic pain, nausea, vomiting, and weight gain. OHSS usually occurs 2 weeks after treatment ends, peaks 7 to 10 days after ovulation, and resolves with menses onset.

If OHSS occurs, drug is withdrawn and patient is hospitalized for bed rest, fluid and electrolyte management, and analgesics. Monitor daily fluid intake and output, weight, abdominal girth, hematocrit, serum and urinary electrolytes, urine specific gravity, blood urea nitrogen, and creatinine. Watch for hemoconcentration caused by fluid loss into peritoneal, pleural, and pericardial cavities.

Stay alert for pulmonary and thromboembolic complications.

• Assess male patient for pituitary insufficiency as possible cause of infertility.

Patient teaching

• Before therapy, teach patient about duration of treatment and necessary monitoring.

• Inform patient about risk of multiple births with menotropins and hCG use.

• For infertile females, encourage daily intercourse starting on day before hCG administration.

• As appropriate, review all other significant and life-threatening adverse reactions.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


Extract of postmenopausal urine containing primarily the follicle-stimulating hormone.
See also: human menopausal gonadotropin, urofollitropin.
Farlex Partner Medical Dictionary © Farlex 2012


Extract of postmenopausal urine that primarily contains the follicle-stimulating hormone.
See also: human menopausal gonadotropin, urofollitropin
Medical Dictionary for the Health Professions and Nursing © Farlex 2012
References in periodicals archive ?
With the addition of Ganirelix, Ferring continues to offer the most complete reproductive medicine portfolio available, which includes Menopur (menotropins for injection), NOVAREL (chorionic gonadotropin for injection, USP) and Endometrin (progesterone) Vaginal Insert.
Ovarian stimulation was initiated with recombinant FSH (rFSH), and the daily dose of either rFSH (Gonal-F, Serono, Germany) or human menopausal gonadotropin (Menopur, Ferring, Germany) adjusted according to the ovarian response.
In control group, COS was induced by administration of 300 IU FSH (Gonadal F; Merck Inc., Germany) and 150 IU human menopausal gonadotrophin (hMG; Menopur; 75 IU Ampules, Ferring Inc., Germany).
On the third cycle, Human Menopausal Gonadotropin (Menopur 225 IU) was administrated for 3 days and then Menopur 150 IU for 5 days.
On the seventh day of treatment, 300 IU of highly purified human menopausal gonadotrophin (Merional, IBSA, Switzerland or Menopur, Ferring, Turkey) were administered, similar to the protocol of Polyzos and Devroey (6), subcutaneously per day to each patient (group 1).
On the same day, ovarian stimulation was carried out with recombinant FSH (follitropin [alpha]; rFSH; Gonal-F, Merck Serono, France, or follitropin [beta]; Puregon, MSD, France), urinary FSH (urofollitropin, Fostimon, France), or hMG (menotropin, Menopur, France) at a starting dose of 75 IU/day from the second day of the cycle.
Ovarian stimulation was started on the second day of menstruation with a daily dose of 125 IU of rFSH (Puregon; MSD, Oss) until the 7th day of stimulation, afterwards, the stimulation continued with a combination of 50 IU of rFSH (Puregon; MSD, Organon) and 75 IU of hMG (Menopur; Ferring, UK).
Despite being offered free gonadotropins (Menopur) for one cycle and a free year of freezing and storage of all extra blastocysts, 48% of couples who were paying out of pocket opted for multiple- rather than single-embryo transfer, and 23.5% of those who had at least one reproductive cycle covered by insurance also refused the free offer, said Dr.
My doctor, who can't make any guarantees, says "that's a good sign." The donor takes drugs--the Follistim and Menopur from my leftover stash--to stimulate follicle (egg) production.
HMG (Repronex, Menopur), an injected medication, is used for women who do not ovulate on their own.
Ovarian stimulation was achieved by administering follicle-stimulating hormone (FSH)/ human chorionic gonadotrophin (HCG) (Menopur) or FSH (Gonal F) alone.